Urology Unit, Cannizzaro Hospital, Catania, Italy;
Urology Unit, Cannizzaro Hospital, Catania, Italy.
Anticancer Res. 2021 Jun;41(6):3127-3130. doi: 10.21873/anticanres.15097.
BACKGROUND/AIM: To evaluate the diagnosis and treatment of prostate cancer (PCa) during 1 year of the COVID-19 pandemic.
The management of men with PCa during COVID-19 pandemic (March 2020-2021) was compared with the clinical activity of the 12 months before the COVID-19 pandemic (March 2019-2020).
The number of clinical visits, prostate biopsy, and men enrolled in active surveillance was significantly lower during the COVID-19 pandemic (p<0.05); on the contrary, the number of cases with advanced (pT3b: 11.2 vs. 25.6%; nodal positive: 14.8 vs. 46.1%) and metastatic (5.9 vs. 9.3%) PCa increased. The number of open radical prostatectomies increased compared with the ones using a laparoscopic approach; moreover, more men were treated with external radiotherapy (25.1 vs. 54.2%).
The guideline recommendations in the management of PCa should constantly adapt to the epidemiological evolution, but the overall cost of delayed diagnosis will increase in the near future.
背景/目的：评估 COVID-19 大流行期间前列腺癌（PCa）的诊断和治疗情况。
比较了 COVID-19 大流行期间（2020 年 3 月至 2021 年）男性 PCa 的治疗管理与 COVID-19 大流行前 12 个月（2019 年 3 月至 2020 年）的临床活动。
COVID-19 大流行期间临床就诊、前列腺活检和接受主动监测的男性数量明显减少（p<0.05）；相反，晚期（pT3b：11.2%比 25.6%；淋巴结阳性：14.8%比 46.1%）和转移性（5.9%比 9.3%）PCa 病例数量增加。与腹腔镜方法相比，开放性根治性前列腺切除术的数量增加；此外，更多的男性接受了外部放射治疗（25.1%比 54.2%）。
PCa 管理中的指南建议应不断适应流行病学的演变，但未来不久，延迟诊断的总体成本将会增加。
